Related Experiment Video
Updated: Feb 3, 2026

Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma
Natasha Alexander1,2, Paula Marrano3, Paul Thorner3,4
1Departments of Pediatrics, Division of Hematology/Oncology.
Abstract:
Alternative radiolabeled, targeted agents are being investigated for children with relapsed neuroblastoma (NB) who do not respond to I-metaiodobenzylguanidine (MIBG) therapy. (DOTA-Tyr)-octreotate targets somatostatin receptors (SSTRs), particularly SSTR2, which are expressed on NB cells. We investigated SSTR2 expression in NB tumors (36 high-risk [HR]; 33 non-HR patients) and correlated SSTR2 levels with clinical features, norepinephrine transporter (NET) expression, and MIBG avidity. SSTR2 and NET immunohistochemistry scores (0 to 3) were calculated on biopsies using digital image analysis based on staining intensity and distribution. Clinical data were correlated with SSTR2 expression. Median SSTR2 score for 69 patients was 1.31 (0.26 to 2.55). Non-HR NB was associated with a higher SSTR2 score (P=0.032). The SSTR2 expression did not correlate with age, International Neuroblastoma Staging System (INSS) stage, MYCN amplification and histology. Higher SSTR2 scores were observed in MIBG-avid versus MIBG-nonavid NB. SSTR2 score was not significantly associated with NET score (r=-0.062, P=0.62). Twenty-six patients who relapsed or progressed had a median SSTR2 score of 1.33 (0.26 to 2.55). Patients with NB including relapsed or progressive disease showed SSTR2 expression at diagnosis, suggesting they could be candidates for radiolabeled-DOTA-conjugated peptide imaging or therapy.
Insights
Neuroblastoma (NB) cells express somatostatin receptors (SSTRs), particularly SSTR2. This study found SSTR2 expression in NB tumors, suggesting potential for targeted peptide therapies in relapsed or refractory neuroblastoma.
Area of Science:
- Pediatric Oncology
- Nuclear Medicine
- Molecular Imaging
Background:
- Relapsed neuroblastoma (NB) poses treatment challenges, especially for patients unresponsive to I-metaiodobenzylguanidine (MIBG) therapy.
- Targeted therapies using radiolabeled agents are being explored for these difficult-to-treat cases.
- Somatostatin receptors (SSTRs), particularly SSTR2, are expressed on NB cells and are targets for agents like (DOTA-Tyr)-octreotate.
Purpose of the Study:
- To investigate somatostatin receptor subtype 2 (SSTR2) expression in neuroblastoma (NB) tumors.
- To correlate SSTR2 levels with clinical features, norepinephrine transporter (NET) expression, and MIBG avidity.
- To assess the potential of SSTR2-targeted agents for NB patients, including those with relapsed or refractory disease.
Main Methods:
- Immunohistochemistry was used to quantify SSTR2 and NET expression scores (0-3) in NB tumor biopsies from 69 patients (36 high-risk, 33 non-high-risk).
- Digital image analysis assessed staining intensity and distribution for SSTR2 and NET.
- Statistical analysis correlated SSTR2 scores with clinical data (age, stage, MYCN amplification, histology), MIBG avidity, and NET expression.
Main Results:
- The median SSTR2 score across 69 patients was 1.31.
- Non-high-risk NB showed significantly higher SSTR2 scores compared to high-risk NB (P=0.032).
- Higher SSTR2 expression was observed in MIBG-avid tumors compared to MIBG-nonavid tumors.
- SSTR2 expression did not correlate with age, INSS stage, MYCN amplification, or histology.
- SSTR2 scores were not significantly associated with NET scores (r=-0.062, P=0.62).
- Patients with relapsed or progressive disease (n=26) had a median SSTR2 score of 1.33.
Conclusions:
- Neuroblastoma tumors, including those in relapsed or progressive disease, express SSTR2 at diagnosis.
- SSTR2 expression suggests that patients with NB may be suitable candidates for targeted imaging or therapy with radiolabeled DOTA-conjugated peptides.
- These findings support the investigation of alternative targeted agents for neuroblastoma management, particularly in MIBG-refractory cases.
Related Concept Videos
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Correlations
Correlation and Causation
Correlation versus Causation
If the dependent variable increases or decreases when the independent variable increases, there is a positive or negative...
Correlation
Two variables, for example, a and b, are said to be positively correlated if both variables move in the same direction. In other words, a positive correlation exists between two variables, a and b, if:
Internal Receptors
Correlation and Regression

